23YER913: A phase II multicenter, open-label, single-arm, dose escalation study of Asciminib monotherapy in 2nd line chronic phase- chronic Myelogenous Leukemia (ASC2ESCALATE)
Principal Investigator
Study Number
STUDY02001913
Summary
This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort). In addition, newly diagnosed CML-CP patients who may have received up to 4 weeks of prior TKI are included in a separate 1L patient cohort.
Phase
II
Contact
Available at the following location(s)
- Lebanon
View more details at ClinicalTrials.gov
Do you need help with some of the labels on this page?
Read our glossary of terms